Using Antibody Profiling to Identify Novel Diagnostic Biomarkers
Unlocking the power of antibody profiling for cancer diagnostics
Current cancer screening methods often lead to false positives, false negatives and invasive biopsies that lack prognostic insights. Emerging research suggests that cancer-specific IgM and IgG antibodies – produced by B cells upon recognizing malignant cells – could serve as stable, easily measurable blood biomarkers for detecting and monitoring high-incidence cancers like melanoma and breast, prostate, bowel, lung and pancreatic cancer. This approach has the potential to improve early diagnosis, reduce uncertainty and enhance treatment planning.
In this webinar, you’ll learn:
- How cancer-specific antibodies (IgM and IgG) can be leveraged as biomarkers for early detection and prognosis
- The advantages of immune-based blood tests over conventional screening and biopsy methods
- Insights into ongoing research exploring the predictive value of antibody reactivity across different cancer stages
Jessica Da Gama Duarte, PhD
Jessica Da Gama Duarte obtained a PhD in Medical Biochemistry at the University of Cape Town, South Africa, in 2015, developing a novel protein microarray-based tumor antigen array. She was recruited as a postdoctoral research fellow by the Olivia Newton-John Cancer Research Institute, in the Cancer Immunobiology Program, to investigate the translational capacity of the array. In 2025, she was recruited by Monash University, School of Translational Medicine, as Laboratory Head and Senior Research Fellow.
Using Antibody Profiling to Identify Novel Diagnostic Biomarkers
A presentation by Jessica Da Gama Duarte
More webinars
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.
WebinarLinking the plasma proteome to echocardiographic parameters in patients with chronic heart failure
Recent advancements in proteomic profiling have unlocked new possibilities for understanding the complex mechanisms that drive heart failure. Measuring thousands of proteins simultaneously makes it possible to capture a comprehensive overview of the patient's health state and investigate underlying disease progression at a subclinical level.
WebinarB Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC
In this webinar, Gary Middleton, MD, PhD, and Akshay Patel, PhD, from the University of Birmingham explore the role of the B cell repertoire and autoantibodies in shaping responses to checkpoint blockade immunotherapy in non-small-cell lung cancer (NSCLC). They demonstrate how autoantibody profiling using the i-Ome™ Discovery protein microarray revealed biomarkers predictive of treatment efficacy and immune-related adverse events (irAEs), providing insights into biomarker development and personalized immunotherapy strategies.